Talk:Hydroxynorketamine
Appearance
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Hydroxynorketamine.
|
Legal status
[edit]Is hydroxynorketamine a scheduled substance (more technically, are any of the hydroxynorketamines scheduled substances) in any jurisdiction, and if so, what jurisdictions assign it to what schedules? Antediluvian67 (talk) 23:26, 13 February 2017 (UTC)
Regarding "Ketamine and metabolites at the NMDAR"
[edit]Drawing from Suzuki K. et al.,(2017), the article states: "a June 2017 study found that (2R,6R)-HNK does in fact block the NMDA receptor, similarly to ketamine.", suggesting that the antidepressant activity of (2R,6R)-HNK may be NMDAR dependent. Significant NMDAR antagonism by this compound was only observed a dosage of 50μM[1], despite the presence of antidepressant effects at only 10μM [2]. OllyTheBug (talk) 01:35, 6 March 2019 (UTC)
References
- ^ Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM (2017). "Effects of a ketamine metabolite on synaptic NMDAR function". Nature. 546 (7659): E1–E3. doi:10.1038/nature22084. PMID 28640258.
- ^ Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Georgiou, Polymnia; Fischell, Jonathan; Elmer, Greg I.; Alkondon, Manickavasagom; Yuan, Peixiong; Pribut, Heather J.; Singh, Nagendra S.; Dossou, Katina S. S.; Fang, Yuhong; Huang, Xi-Ping; Mayo, Cheryl L.; Wainer, Irving W.; Albuquerque, Edson X.; Thompson, Scott M.; Thomas, Craig J.; Zarate Jr, Carlos A.; Gould, Todd D. (2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533: 481–486. doi:10.1038/nature17998. ISSN 0028-0836. PMC 4922311. PMID 27144355.